Skip to content

Pharminent

cropped-ChatGPT-Image-May-28-2026-10_46_23-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Clinical Data
  • Parkinson’s drug from Biogen, Denali comes up short
  • Clinical Data

Parkinson’s drug from Biogen, Denali comes up short

BioPharma Dive

High-level results have led the companies to scrap the mid-stage trial, though Denali plans to continue independently running a separate experiment focused on a certain subset of Parkinson s patients.

Neuroscience

Read full story

pharminent May 22, 2026 (Last updated: May 22, 2026)

BioPharma Dive

High-level results have led the companies to scrap the mid-stage trial, though Denali plans to continue independently running a separate experiment focused on a certain subset of Parkinson s patients.

Neuroscience

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival
Next: Next Post

Related Stories

  • Clinical Data

ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data

pharminent June 9, 2026
  • Clinical Data

ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction

pharminent June 8, 2026
  • Clinical Data

Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data

pharminent June 5, 2026

You May Have Missed

  • M&A / Deals

Alzecure enters collaboration and with Lilly for Alzheimer’s project

pharminent June 9, 2026
  • Clinical Data

ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data

pharminent June 9, 2026
  • M&A / Deals

GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year

pharminent June 9, 2026
  • Regulatory

ADA: Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval

pharminent June 9, 2026
Copyright © 2026 All rights reserved. | ReviewNews by AF themes.